For those diagnosed with advanced lung cancer, there is often the question of how lifestyle changes can improve the prognosis. A unique study in Italy called EXcellenT will measure how supervised exercise affects outcomes. Those who have a positive biomarker, like ALK, can participate if they are on their first or second tyrosine kinase inhibitor (TKI). Participants will be randomly divided into two groups, the experimental group and control group. The experimental group will be assigned a home-based exercise program that is directed and monitored by entries in a smartphone app.
Read MoreThose in the ALK community fear the day when progression occurs after Lorlatinib, the “last” ALK inhibitor available. Although there are effective treatments after Lorlatinib, there is no standard treatment. Without a specified FDA-approved treatment, people must face Lorlatinib resistance without knowing the best strategy.
Read MoreIn recent years, a signal pathway called HIPPO, which is important in angiogenesis (blood vessel growth), has become important for the ALK cancer realm. There has been accumulating evidence that a protein called YAP (Yes Associated Protein-1) can prevent TKI-resistant cells from developing resistance in vitro and in vivo (in laboratory experiments and in cell experiments). This pathway is very important as there is evidence that it is very well-preserved in evolution - there are homologs to humans in Drosophila (fruit flies).
Read MoreOn the ALK Positive Support Group pages, I see photos of smiling, loving families having incredible adventures while living with an unpredictable and unrelenting illness. Our family has taken the same snapshots with my husband smiling in the center, his face showing no signs of stage 4 lung cancer. These pictures show the tremendous well of love and resilience we all tap into every day. But on some days, I look at these families and see my own weaknesses. The others seem to be managing this illness so well, so positively, while I wrestle with an obscured future.
Read MoreLinnea Olsen, along with many other long-term ALK-positive lung cancer survivors, participated in clinical trials at several junctures in treatment. Linnea participated in a trial of Crizotinib, the first treatment for ALK-positive lung cancer. She joined 5 more clinical trials over the course of her illness. By enrolling in clinical trials, she was able to get advanced treatments before they were approved for general medical use.
Read MoreJust in time for Lung Cancer Awareness Month, ALK Positive, Inc. is presenting a website where you or your clinician can search for clinical trials that are recruiting for ALK-positive lung cancer. ALK Positive has partnered with ClinWiki, a non-profit who provides a free web-based application to help patients with serious illnesses understand their clinical trial options.
Read More